Centrosomal P4.1-associated protein (CPAP, also called CENPJ), which is positively correlated with recurrence and vascular invasion in HCC and contributes to sorafenib resistance (Chen et al., 2020), could be a therapeutic target for inhibiting angiogenesis and treating metastatic HCC. The gene discussed is CPAP; the disease is hepatocellular carcinoma.